LAG-3

[Immunity] Researchers investigated the relative contribution of potential ligands, stable peptide-MHC class II complexes and fibrinogen-like protein 1, to lymphocyte activation gene-3 (LAG-3) activity in vitro and in vivo.

[Immunity] Researchers investigated the relative contribution of potential ligands, stable peptide-MHC class II complexes and fibrinogen-like protein 1, to lymphocyte activation gene-3 (LAG-3) activity in vitro and in vivo.

[Nature Immunology] Researchers showed that type 1 interferon regulated coinhibitory receptor expression on human T cells, inducing PD-1/TIM-3/LAG-3 while inhibiting T cell immunoreceptor with immunoglobulin and ITIM domains expression.

[Immutep Limited] Immutep Limited announced the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office directed to pharmaceutical compositions for use in the treatment of cancer.

[Scientific Reports] Mechanistic insights demonstrated that blockade of the PD-1 axis decreased stem-like marker ALDH and expression of DNA repair genes.

[Reproductive Sciences] Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.